ClinicalTrials.gg
Not yet recruitingNCT07547384Updated Apr 23, 2026

Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia.

An interventional study of Aripiprazole for Injection and Aripiprazole for Injection in Schizophrenia, sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Planned enrollment
69th of 125
116 · median 130
Started
2026
with 1 other
No phase
13 of 126
1 open now
Registered
125th of 126
by date

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 69th largest by planned enrollment of the 125 interventional ones that give a count, is one of 2 that started in 2026, is one of 13 with no phase, and was the 125th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the bioequivalence of aripiprazole for injection (Test product, 400 mg) compared with Abilify Maintena® (Reference product, 400 mg) at steady state in patients with schizophrenia.his is a multi-center, randomized, open-label, two-period, crossover study. Approximately 116 clinically stable patients will be enrolled and randomly assigned to one of two treatment sequences: Sequence A (Test-Reference) or Sequence B (Reference-Test). In each 141-day study period, participants will receive five injections of either the test or reference product at 28-day intervals to achieve steady-state plasma concentrations. Bioequivalence, safety and tolerability of the study drug will be assessed in this study.

Read the detailed description

Purpose: The primary objective of this study is to evaluate the steady-state bioequivalence between Aripiprazole for Injection (400 mg) manufactured by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (Test product) and Abilify Maintena® (400 mg) manufactured by Otsuka Pharmaceutical (Reference product) in Chinese patients with stable schizophrenia.

Methods: This is a multicenter, randomized, open-label, two-period, crossover, multiple-dose,steady-state bioequivalence study. Approximately 116 eligible patients with stable schizophrenia will be randomly assigned to one of two treatment sequences (Test-Reference or Reference-Test). In each period, subjects will receive five intramuscular injections of either the Test or Reference product (400 mg) at 28-day intervals to ensure that steady-state blood concentrations are achieved by the fourth dose.

Primary Endpoints: Pharmacokinetic (PK) samples will be collected to determine the steady-state maximum plasma concentration (Cmax,ss) and the area under the plasma concentration-time curve over the dosing interval at steady state (AUCτ,ss).

Safety: The safety and tolerability of both formulations will also be monitored and compared throughout the trial.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Aged 18 to 65 years (inclusive), male or female.
  • 2. Patients diagnosed with schizophrenia according to ICD-10 criteria, with a Positive and Negative Syndrome Scale (PANSS) total score ≤ 70, judged as clinically stable for at least 28 days prior to screening (no medication changes or hospitalization due to condition changes).
  • 3. Receiving treatment with ≤ 2 other oral antipsychotic medications, which must have been at a stable dose for ≥ 14 days before the first study injection (excluding prohibited medications).
  • 4. Body weight ≥ 45 kg for females and ≥ 50 kg for males; (BMI) between 18.5 and 35.0 kg/m² (inclusive).
  • 5. Subject or partner has no pregnancy plan and agrees to use effective non-drug during the study and for six months after the last dose.
  • 6. Subjects and their legal guardians voluntarily sign the Form (ICF) and are able to comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  • 1.Diagnosis of any psychiatric disorder other than schizophrenia according to ICD-10 criteria.
  • 2.History or presence of cardiovascular, hepatic, renal, gastrointestinal, psychiatric, or neurological diseases that, in the investigator's judgment, would affect participation in the study.
  • 3.Patients with Parkinson's disease, Lewy body dementia, or dementia-related psychosis.
  • 4.History or presence of Neuroleptic Malignant Syndrome (NMS).
  • 5.History or presence of epilepsy or convulsive disorders (except childhood febrile seizures), or a history of stroke or (TIA) within one year before signing the Form (ICF).
  • 6.Concurrent tardive dyskinesia (or history) or severe akathisia.
  • 7.Esophageal motility dysfunction or dysphagia with a potential risk of aspiration pneumonia.
  • 8.Cardiovascular Risks: Congenital long syndrome; presence of uncontrolled or significant cardiovascular disease, including Class II or higher heart failure, unstable angina, myocardial infarction, or significant arrhythmia/frequent ventricular premature beats within 6 months before the first dose; QTcF > 450 ms in males or > 470 ms in females; presence of risk factors for Torsades de Pointes or sudden death (such as bradycardia, clinically significant hypokalemia, or current use of QTc-prolonging medications; excluding bradycardia judged by the investigator to be risk-controllable and stable after treatment, corrected hypokalemia, or instances where QTc-prolonging medications are discontinued or evaluated as acceptable for stable use) or other clinically significant abnormalities judged by the investigator as potentially affecting subject safety or interfering with study participation.
  • 9.Blood Pressure Abnormalities: Poorly controlled hypertension (SBP > 160 mmHg and/or DBP > 100 mmHg after stable antihypertensive treatment); symptomatic hypotension; or orthostatic hypotension (SBP drop ≥ 20 mmHg or DBP drop ≥ 10 mmHg within 3 minutes of standing during screening or baseline).
  • 10.Glycosylated () level ≥ 7% at screening or baseline.
  • 11.Laboratory Abnormalities: 1) TBiL > 1.5 × , or /ALT > 2 × ULN; 2) \< 90 mL/min; 3) WBC \< 3 × 10⁹/L, Neutrophils \< 1.5 × 10⁹/L, \< 75 × 10⁹/L, RBC \< 3.0 × 10¹²/L, or Hemoglobin \< 100 g/L.
  • 12.Positive results for , -Ab, -Ab, or Syphilis-Ab that, in the investigator's judgment, affect study participation.
  • 13.Severe Suicide Risk: 1) Positive response to item 4 or 5 of "suicidal ideation" on C-SSRS within the past 6 months; 2) History of suicidal behavior within the past 6 months; or 3) Judged by the investigator to have a severe suicide risk.
  • 14.Received electroconvulsive therapy (ECT) or invasive psychiatric treatment within 28 days before signing the ICF.
  • 15.History of Blood Loss: Blood loss ≥ 400 mL within 3 months or ≥ 200 mL within 1 month before signing the ICF.
  • 16.Major surgery within 3 months before signing the ICF, or planned surgery during the study or within one month after study completion.
  • 17.Other Clinical Studies: Participation in any other drug clinical study within one month before the first dose (except for aripiprazole BE studies).
  • 18.Long-acting Injectable (LAI) History: Prior treatment with non-aripiprazole LAIs where the interval since the last dose is shorter than the labeled dosing interval of that LAI; or a requirement for other LAIs during the study.
  • 19.Medication : Use of Chlorpromazine or Thioridazine within 28 days before the first dose; or use of strong/moderate or CYP2D6 inhibitors or inducers within 14 days or five half-lives (whichever is longer).
  • 20.Consumption of foods or beverages rich in xanthines, grapefruit, or caffeine within 48 hours before the first dose, or other special diets that could affect drug pharmacokinetics.
  • 21.History of drug abuse, drug usage, or positive drug screening within one year before signing the ICF.
  • 22.Chronic Alcohol Consumption: Males > 14 units/week, females > 7 units/week (1 unit ≈ 10g pure alcohol).
  • 23.History of needle phobia or blood phobia judged by the investigator to be clinically significant.
  • 24.Known or suspected to the study drug or any of its components.
  • 25.Female Status: Women who are pregnant, breastfeeding, or planning to become pregnant (excludes those for ≥ 1 year or surgically sterilized).
  • 26.Other conditions that the investigator deems unsuitable for participation in the study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Sequence A (Test - Reference)

    Participants receive the Test product (400 mg) in Period 1 and the Reference product (400 mg) in Period 2.

    Drug: Aripiprazole for Injection

  • Active comparator
    Sequence B (Reference - Test)

    Participants receive the Reference product (400 mg) in Period 1 and the Test product (400 mg) in Period 2.

    Drug: Aripiprazole for Injection

Interventions

  • Subjects will receive a dose of 400 mg (approximately 2 mL) of the test product. The medication is administered via deep intramuscular injection into the gluteal muscle once every 28 days (±1 day). In each study period, subjects will receive a total of 5 injections to ensure steady-state concentrations are achieved.

    Also known as: SYH9096

  • Subjects will receive a dose of 400 mg (400 mg/2 mL) of the reference product. The medication is administered via deep intramuscular injection into the gluteal muscle once every 28 days (±1 day). In each study period, subjects will receive a total of 5 injections to maintain consistent exposure levels for bioequivalence comparison.

    Also known as: Abilify Maintena®

06

What researchers measure

Primary outcomes

  1. Steady-state Maximum Plasma Concentration (Cmax,ss) of Aripiprazole

    The observed maximum concentration of aripiprazole in plasma at steady state following the 5th intramuscular injection (400 mg) in each study period

    Time frame: Period 1: Day 113 to Day 141 ; Period 2: Day 253 to Day 281

  2. Area Under the Plasma Concentration-time Curve Over the Dosing Interval at Steady State (AUCτ,ss) of Aripiprazole.

    The area under the plasma concentration-time curve for aripiprazole calculated over a dosing interval (28 days) at steady state using the linear up-log down rule.

    Time frame: Period 1: Day 113 to Day 141 ; Period 2: Day 253 to Day 281

Secondary outcomes

  1. Time to Maximum Plasma Concentration (Tmax,ss) of Aripiprazole at Steady State.

    The time to reach the maximum observed plasma concentration of aripiprazole after multiple dosing at steady state.

    Time frame: Period 1: Day 113 to Day 141; Period 2: Day 253 to Day 281

  2. Trough Plasma Concentration (Ctau,ss) of Aripiprazole at Steady State.

    The plasma concentration measured at the end of a dosing interval at steady state.

    Time frame: Period 1: Day 113 to Day 141; Period 2: Day 253 to Day 281

  3. Minimum Plasma Concentration (Cmin,ss) of Aripiprazole at Steady State.

    The minimum observed plasma concentration during a dosing interval at steady state.

    Time frame: Period 1: Day 113 to Day 141; Period 2: Day 253 to Day 281

  4. Terminal Elimination Half-life (t1/2,ss) of Aripiprazole at Steady State.

    The time required for the plasma concentration of aripiprazole to decrease by half during the terminal phase at steady state.

    Time frame: Period 1: Day 113 to Day 141; Period 2: Day 253 to Day 281.

  5. Fluctuation Factor (DF) of Aripiprazole at Steady State.

    (Cmax,ss-Cmin,ss)/ Cav,ss

    Time frame: Period 1: Day 113 to Day 141; Period 2: Day 253 to Day 281.

  6. Steady-state Average Concentration (Cav,ss) of Aripiprazole.

    Average concentration at steady state.

    Time frame: Period 1: Day 113 to Day 141; Period 2: Day 253 to Day 281.

  7. Terminal Elimination Rate Constant (λz,ss) of Aripiprazole at Steady State.

    The rate at which aripiprazole is removed from the body.

    Time frame: Period 1: Day 113 to Day 141; Period 2: Day 253 to Day 281.

  8. Swing of Aripiprazole at Steady State.

    (Cmax,ss-Cmin,ss)/ Cmin,ss.

    Time frame: Period 1: Day 113 to Day 141; Period 2: Day 253 to Day 281.

  9. Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs).

    Assessment of safety and tolerability by monitoring the frequency and severity of AEs, SAEs, and changes in laboratory tests, 12-lead ECG, physical examinations, and vital signs.

    Time frame: Day1 to Day281.

  10. CGI Score

    The CGI-S is a 7-point scale that measures the clinician's assessment of the severity of the patient's mental illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Day1 to Day281.

  11. C-SSRS

    The Columbia-Suicide Severity Rating Scale (C-SSRS) assesses suicidal ideation and behavior.

    Time frame: Day1 to Day281

  12. BARS Score

    The BARS is used to assess the severity of drug-induced akathisia. The Global Clinical Assessment score ranges from 0 (absent) to 5 (severe).

    Time frame: Day1 to Day281

  13. AIMS Score

    The AIMS is used to assess the presence and severity of tardive dyskinesia. The total score is the sum of items 1 through 7, with each item rated from 0 (none) to 4 (severe).

    Time frame: Day1 to Day281

  14. SAS Score

    The SAS is used to assess extrapyramidal symptoms. It consists of 10 items, each rated on a 5-point scale (0 to 4).

    Time frame: Day1 to Day281

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Sep 2027, 17 months later.

Of 769 interventional studies with no phase under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Apr 23, 2026
StartEst.
Apr 5, 2026
Primary completionEst.
Sep 5, 2027
CompletionEst.
Nov 5, 2027
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07547384
Responsible party
Sponsor
First posted
Apr 23, 2026
Start date
Apr 5, 2026 (estimated)
Primary completion
Sep 5, 2027 (estimated)
Completion
Nov 5, 2027 (estimated)
Last update
Apr 23, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion